Alembic Pharma JV gets USFDA nod to Desonide Lotion
Desonide Lotion is low to medium potency corticosteroids indicated for the relief of the Inflammatory and pruritic manifestations of corticosteroid responsive dermatoses.
Vadodara: Alembic Pharmaceuticals Limited has recently announced that its joint venture Aleor Dermaceuticals Limited has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Desonide Lotion, 0.05%.
The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), DesOwen® Lotion, 0.05% of Galderma Laboratories LP.
Desonide Lotion is low to medium potency corticosteroids indicated for the relief of the Inflammatory and pruritic manifestations of corticosteroid responsive dermatoses.
Desonide Lotion, 0.05% has an estimated market size of US$ 7 million for twelve months ending June 2020 according to IQVIA.
Alembic has a cumulative total of 129 ANDA approvals (113 final approvals and 16 tentative approvals) from USFDA.
Read also: Alembic Pharma JV Gets Tentative USFDA Nod To Antifungal Drug Tavaborole Topical Solution
Alembic Pharmaceuticals Limited, a vertically integrated research and development pharmaceutical company headquartered in Gujarat.
Alembic is a publicly listed company that manufactures and markets generic pharmaceutical products all over the world.
Read also: Alembic Pharma Raises Rs 750 Crores Via QIP Issue
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd